Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
10 min read
Erythroplasia of Queyrat Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
7 August 2026
2026 Erythroplasia of Queyrat strategy covering epidemiology, unmet need, target biology, clinical competition and deal signals, built with PatSnap MCP evidence.
Latest Hotspot
10 min read
Disseminated superficial actinic porokeratosis Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
7 August 2026
2026 Disseminated superficial actinic porokeratosis strategy covering epidemiology, unmet need, target biology, clinical competition and deal signals, built with.
Latest Hotspot
10 min read
Xanthelasma Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
7 August 2026
Explore the 2026 Xanthelasma indication strategy: epidemiology, unmet need, target biology, clinical competition and deal signals using PatSnap MCP evidence.
Latest Hotspot
10 min read
Calciphylaxis cutaneous Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
7 August 2026
2026 Calciphylaxis cutaneous strategy covering epidemiology, unmet need, target biology, clinical competition and deal signals, built with PatSnap MCP evidence.
Latest Hotspot
10 min read
Eruptive xanthomas Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
7 August 2026
Explore the 2026 Eruptive xanthomas indication strategy: epidemiology, unmet need, target biology, clinical competition and deal signals using PatSnap MCP evidence.
Latest Hotspot
10 min read
Scleredema adultorum Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
7 August 2026
2026 Scleredema adultorum strategy covering epidemiology, unmet need, target biology, clinical competition and deal signals, built with PatSnap MCP evidence.
Latest Hotspot
10 min read
Linear morphea Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
7 August 2026
Explore the 2026 Linear morphea indication strategy: epidemiology, unmet need, target biology, clinical competition and deal signals using PatSnap MCP evidence.
Latest Hotspot
10 min read
Lipodermatosclerosis Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
7 August 2026
2026 Lipodermatosclerosis strategy covering epidemiology, unmet need, target biology, clinical competition and deal signals, built with PatSnap MCP evidence.
Latest Hotspot
10 min read
Erythema induratum Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
7 August 2026
Explore the 2026 Erythema induratum indication strategy: epidemiology, unmet need, target biology, clinical competition and deal signals using PatSnap MCP evidence.
Latest Hotspot
10 min read
Weber-Christian disease Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
7 August 2026
2026 Weber-Christian disease strategy covering epidemiology, unmet need, target biology, clinical competition and deal signals, built with PatSnap MCP evidence.
Latest Hotspot
10 min read
Panniculitis Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
7 August 2026
Explore the 2026 Panniculitis indication strategy: epidemiology, unmet need, target biology, clinical competition and deal signals using PatSnap MCP evidence.
Latest Hotspot
10 min read
Subcutaneous granuloma annulare Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
7 August 2026
2026 Subcutaneous granuloma annulare strategy covering epidemiology, unmet need, target biology, clinical competition and deal signals, built with PatSnap MCP.